Tissue‐Targeted Drug Delivery Strategies to Promote Antigen‐Specific Immune Tolerance
Source abstract
Abstract
Abstract During autoimmunity or organ transplant rejection, the immune system attacks host or transplanted tissue, causing debilitating inflammation for millions of patients. There is no cure for most of these diseases. Further, available therapies modulate inflammation through nonspecific pathways, reducing symptoms but also compromising patients’ ability to mount healthy immune responses. Recent preclinical advances to regulate immune dysfunction with vaccine‐like antigen specificity reveal exciting opportunities to address the root cause of autoimmune diseases and transplant rejection. Several of these therapies are currently undergoing clinical trials, underscoring the promise of antigen‐specific tolerance. Achieving antigen‐specific tolerance requires precision and often combinatorial delivery of antigen, cytokines, small molecule drugs, and other immunomodulators. This can be facilitated by biomaterial technologies, which can be engineered to orient and display immunological cues, protect against degradation, and selectively deliver signals to specific tissues or cell populations. In this review, some key immune cell populations involved in autoimmunity and healthy immune tolerance are described. Opportunities for drug delivery to immunological organs are discussed, where specialized tissue‐resident immune cells can be programmed to respond in unique ways toward antigens. Finally, cell‐ and biomaterial‐based therapies to induce antigen‐specific immune tolerance that are currently undergoing clinical trials are highlighted.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Immunotherapy and Immune Responses · T-cell and B-cell Immunology · RNA Interference and Gene Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Fischell Department of Bioengineering University of Maryland College Park MD 20742 USA
Biological Sciences Training Program University of Maryland College Park MD 20742 USA
US Department of Veterans Affairs VA Maryland Health Care System Baltimore MD 21201 USA
Robert E. Fischell Institute for Biomedical Devices College Park MD 20742 USA
Department of Microbiology and Immunology University of Maryland Medical School Baltimore MD 21201 USA
Funding
National Institutes of Health · U.S. Department of Veterans Affairs
References (100+)
Show source-provided references
1. 10.1016/S0140-6736(13)60954-X10.1016/S0140-6736(13)60954-X ↗
2. 10.1111/joim.1239510.1111/joim.12395 ↗
3. 10.12691/ijcd-3-4-810.12691/ijcd-3-4-8 ↗
4. 10.1016/S1474-4422(10)70028-410.1016/S1474-4422(10)70028-4 ↗
5. 10.1016/j.trre.2018.07.00110.1016/j.trre.2018.07.001 ↗
6. 10.1111/tid.1340710.1111/tid.13407 ↗
7. 10.1002/adtp.20180015710.1002/adtp.201800157 ↗
8. 10.1002/adhm.20180141910.1002/adhm.201801419 ↗
9. 10.1038/ni.373110.1038/ni.3731 ↗
10. 10.1016/j.jaut.2019.10238210.1016/j.jaut.2019.102382 ↗
11. 10.3389/fimmu.2019.0130610.3389/fimmu.2019.01306 ↗
12. 10.1038/nri347710.1038/nri3477 ↗
13. 10.1038/nm119710.1038/nm1197 ↗
14. 10.1038/ni.220710.1038/ni.2207 ↗
15. 10.1038/s41423-019-0324-z10.1038/s41423-019-0324-z ↗
16. 10.4049/jimmunol.090242010.4049/jimmunol.0902420 ↗
17. 10.1084/jem.2011046610.1084/jem.20110466 ↗
18. 10.1016/j.it.2020.11.00110.1016/j.it.2020.11.001 ↗
19. 10.1073/pnas.182003911610.1073/pnas.1820039116 ↗
20. 10.1016/S2213-8587(20)30104-210.1016/S2213-8587(20)30104-2 ↗
21. 10.1016/j.immuni.2020.11.00610.1016/j.immuni.2020.11.006 ↗
22. 10.1084/jem.2017145010.1084/jem.20171450 ↗
23. 10.1038/s41586-020-2814-710.1038/s41586-020-2814-7 ↗
24. 10.1126/science.abj822210.1126/science.abj8222 ↗
25. 10.1038/s41586-022-04432-710.1038/s41586-022-04432-7 ↗
26. 10.1016/S0140-6736(19)31817-310.1016/S0140-6736(19)31817-3 ↗
27. 10.1056/NEJMoa160646810.1056/NEJMoa1606468 ↗
28. 10.1038/s41467-021-22230-z10.1038/s41467-021-22230-z ↗
29. 10.1016/j.celrep.2019.10.01810.1016/j.celrep.2019.10.018 ↗
30. 10.1016/j.cmet.2020.03.00310.1016/j.cmet.2020.03.003 ↗
31. 10.1038/s41586-021-04248-x10.1038/s41586-021-04248-x ↗
32. 10.1038/nri387110.1038/nri3871 ↗
33. 10.1073/pnas.030868910010.1073/pnas.0308689100 ↗
34. 10.1073/pnas.191530911610.1073/pnas.1915309116 ↗
35. 10.1038/ni.181810.1038/ni.1818 ↗
36. 10.1038/s41590-018-0120-410.1038/s41590-018-0120-4 ↗
37. 10.1126/science.116006210.1126/science.1160062 ↗
38. 10.1038/s41590-018-0280-210.1038/s41590-018-0280-2 ↗
39. 10.1084/jem.2003157910.1084/jem.20031579 ↗
40. 10.2337/diabetes.54.1.9210.2337/diabetes.54.1.92 ↗
41. 10.1038/s41598-018-25574-710.1038/s41598-018-25574-7 ↗
42. 10.1136/bmj.m373410.1136/bmj.m3734 ↗
43. Bluestone Jeffrey A. · Sci. Transl. Med. · 2015 · 7
44. 10.1016/j.immuni.2015.10.01110.1016/j.immuni.2015.10.011 ↗
45. 10.1038/nature2232910.1038/nature22329 ↗
46. 10.1126/scitranslmed.300207610.1126/scitranslmed.3002076 ↗
47. 10.1126/scitranslmed.abf526410.1126/scitranslmed.abf5264 ↗
48. Masteller E. L. · 2006 · 103
49. 10.1038/ni.269110.1038/ni.2691 ↗
50. 10.1016/j.jaut.2015.08.02010.1016/j.jaut.2015.08.020 ↗
51. 10.1016/j.jhep.2014.04.02710.1016/j.jhep.2014.04.027 ↗
52. 10.1038/s41575-018-0020-y10.1038/s41575-018-0020-y ↗
53. 10.1038/s41551-019-0424-110.1038/s41551-019-0424-1 ↗
54. 10.1016/j.biomaterials.2019.11943210.1016/j.biomaterials.2019.119432 ↗
55. 10.1021/acsnano.9b0144410.1021/acsnano.9b01444 ↗
56. 10.1021/acsnano.0c0920610.1021/acsnano.0c09206 ↗
57. 10.1021/acsnano.1c0571310.1021/acsnano.1c05713 ↗
58. 10.1016/j.ymthe.2021.06.00410.1016/j.ymthe.2021.06.004 ↗
59. 10.1002/jbm.a.3597010.1002/jbm.a.35970 ↗
60. 10.3389/fimmu.2022.84335510.3389/fimmu.2022.843355 ↗
61. 10.1021/acsnano.7b0699510.1021/acsnano.7b06995 ↗
62. 10.1021/acsnano.7b0111010.1021/acsnano.7b01110 ↗
63. 10.1038/s41565-020-0669-610.1038/s41565-020-0669-6 ↗
64. 10.1038/nm.356810.1038/nm.3568 ↗
65. 10.1084/jem.2013119910.1084/jem.20131199 ↗
66. 10.1084/jem.2012184910.1084/jem.20121849 ↗
67. 10.1016/j.immuni.2011.07.00210.1016/j.immuni.2011.07.002 ↗
68. 10.1038/nature1133710.1038/nature11337 ↗
69. 10.1038/nrd215310.1038/nrd2153 ↗
70. 10.1126/sciadv.abc931710.1126/sciadv.abc9317 ↗
71. 10.1016/j.xphs.2017.06.00810.1016/j.xphs.2017.06.008 ↗
72. 10.1126/scitranslmed.300651610.1126/scitranslmed.3006516 ↗
73. 10.1016/j.nano.2020.10229110.1016/j.nano.2020.102291 ↗
74. 10.1038/s41551-021-00786-x10.1038/s41551-021-00786-x ↗
75. 10.1002/adma.20180511610.1002/adma.201805116 ↗
76. 10.1021/acsnano.1c1137410.1021/acsnano.1c11374 ↗
77. 10.1126/sciimmunol.aau608510.1126/sciimmunol.aau6085 ↗
78. 10.1111/ajt.1233310.1111/ajt.12333 ↗
79. 10.1097/SLA.0b013e318148512410.1097/SLA.0b013e3181485124 ↗
80. 10.4049/jimmunol.190012710.4049/jimmunol.1900127 ↗
81. 10.3389/fimmu.2018.0028110.3389/fimmu.2018.00281 ↗
82. 10.1073/pnas.140868611110.1073/pnas.1408686111 ↗
83. 10.1126/science.aay363810.1126/science.aay3638 ↗
84. 10.1038/s41467-019-11338-y10.1038/s41467-019-11338-y ↗
85. 10.1038/s41551-021-00738-510.1038/s41551-021-00738-5 ↗
86. 10.1111/imr.1238210.1111/imr.12382 ↗
87. 10.1182/blood-2010-11-32002810.1182/blood-2010-11-320028 ↗
88. 10.4049/jimmunol.100417510.4049/jimmunol.1004175 ↗
89. 10.1016/j.jconrel.2019.04.02310.1016/j.jconrel.2019.04.023 ↗
90. 10.1021/jacs.0c0185310.1021/jacs.0c01853 ↗
91. 10.1039/D0BM01609H10.1039/D0BM01609H ↗
92. 10.1097/TP.000000000000277410.1097/TP.0000000000002774 ↗
93. 10.1038/ni113410.1038/ni1134 ↗
94. 10.1073/pnas.110520010810.1073/pnas.1105200108 ↗
95. 10.1016/j.celrep.2016.08.03310.1016/j.celrep.2016.08.033 ↗
96. 10.1007/s12274-019-2301-310.1007/s12274-019-2301-3 ↗
97. 10.1016/j.jconrel.2017.04.02410.1016/j.jconrel.2017.04.024 ↗
98. 10.1038/s41578-019-0110-710.1038/s41578-019-0110-7 ↗
99. 10.1172/jci.insight.12602510.1172/jci.insight.126025 ↗
100. 10.3389/fimmu.2021.71484210.3389/fimmu.2021.714842 ↗